ONCrg Sentinel
Monthly Surveillance Reports

Why We Make a Difference

Proficient + Discerning = Best-In-Class
ONCrg Best In Class

Since our CI experts are highly proficient in conducting surveillance and are already on the cutting-edge of knowledge in their cancer areas, they can run extensive searches and are adept at discerning what new scientific, clinical and market events impact their landscapes and can provide intelligent insight to clients about the future marketplace.

Our analysts vigilantly monitor multiple secondary and primary sources to comprehensively cover clinical trials, product developments, company activities, and regulatory news to deliver monthly reports with unparalleled CI value.

ONCrg Sentinel™TrialsProductsCompaniesRegulatory
ONCrg Sentinel:
ONCrg specialists vigilantly monitor scientific, clinical and commercial developments via multiple secondary and primary sources to provide expert CI support year-round with succinct but comprehensive analyses of market changes and new data releases.
Trials:
Our comprehensive coverage of clinical trials include a brief write up about estimated completion date changes, significant enrollment changes, and clinical trials on hold or terminated and why. More detailed analysis and insights are provided for new and completed clinical trials Ph I/II and greater.
Products:
We look for information that is scientifically and clinically relevant to our pipelines (all drugs in Phase I/II development and beyond), whether it is regulatory news, product news, company news, or clinical trial news.
Companies:
Our analysis of company news includes coverage of research, development and marketing collaborations, alliances, mergers, acquisitions, IPOs and major funding activities, and other major commercial developments in oncology.
Regulatory:
Our analysis of regulatory news includes coverage of FDA approvals, breakthrough therapy designations, Orphan Drug designations, BLA submissions, as well as European Commission, NICE and other major regional activities.

Oncology Coverage

Our best-in-class competitive intelligence coverage serves commercial, medical and scientific teams worldwide.
Solid Tumors
GI - Gastrointestinal GU - Genitourinary Breast / Gyn Lung Other
Colorectal Bladder Breast NSCLC Gliomas
Esophageal Prostate Endometrial SCLC HNSCC
Gastric RCC Ovarian   Melanoma
HCC       STS
Pancreatic        
         
Immuno-Oncology
MOAs
Hematologic Malignancies
Emerging IO ADC ALL MDS MPNs
Late Stage IO Cell Therapies AML MM NHL
  DDR CLL    
Our best-in-class competitive intelligence coverage serves commercial, medical and scientific teams worldwide.
Solid Tumors
GI - Gastrointestinal GU - Genitourinary
Colorectal Bladder
Esophageal Prostate
Gastric RCC
HCC  
Pancreatic  
Breast / Gyn Lung Other
Breast NSCLC Gliomas
Endometrial SCLC HNSCC
Ovarian   Melanoma
    STS
     
Immuno-Oncology
MOAs
Emerging IO ADC
Late Stage IO Cell Therapies
  DDR
   
Hematologic Malignancies
ALL MDS MPNs
AML MM NHL
CLL    

We earn a wide range of endorsements

    Information and Sample Requests
    To learn more about our reports, services, and CI support, please fill out the form below or call us at 650.485.2626.
    *Please note, we will not share your details outside of our company